ProCE Banner Activity

Neoadjuvant Palbociclib + Anastrozole in ER+/HER2- Breast Cancer

Slideset Download
Conference Coverage
This single-arm phase II study demonstrated enhanced cell cycle arrest with the addition of palbociclib to neoadjuvant anastrozole in patients with ER+/HER2- early breast cancer.

Released: December 16, 2015

Expiration: December 14, 2016

No longer available for credit.

Share

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Genentech BioOncology

Novartis Pharmaceuticals Corporation